For the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis

AkebiaCares

Your partner in helping patients access the medication they need

They are extremely easy to work with. I am very thankful for having that support for my patients and them always being available.

Constance Nicastro-Bowman, CNP Nurse Practitioner

Coverage solutions
made simple

MEDICARE LIS/DUAL ELIGIBLE

  • AURYXIA is widely available through Medicare part D plans1
    • Provide insurance reimbursement support based on patient's coverage
    • Depending on the Medicare Part D insurance plan, a medical exception or prior authorization form may be required
  • All Medicare full Low-Income Subsidy (LIS)/dual-eligible patients can pay no more than $11.00 per fill of AURYXIA

COMMERCIAL INSURANCE

  • AURYXIA is covered through the majority of commercial health plans1

UNINSURED/MEDICARE PART D

  • FREE AURYXIA may be provided to eligible patients:
    • Who don’t have insurance
    • Who have Medicare Part D insurance but cannot afford their
      copays
    • Whose insurance does not cover AURYXIA

FIND SUPPORT OPTIONS

AkebiaCares provides eligible patients with coverage support and medicines at no cost

Artistic representation of a customer service representative speaking into a headset

REIMBURSEMENT HELP

One-on-one support for assistance with insurance questions and challenges

Artistic representation of three CKD patients standing together

PATIENT ASSISTANCE PROGRAMS (PAP)

Free AURYXIA may be available for eligible patients with Medicare Part D insurance

  • For patients who are uninsured or have other coverage concerns, AkebiaCares offers comprehensive patient services that may be able to help
Artistic representation of a dollar bill

COPAY CARD

Financial assistance for patients with commercial insurance§

*Restrictions may apply. Copay assistance is not valid for prescriptions reimbursed under Medicare, Medicaid, or similar federal or state programs.

Patients with an income of up to 600% Federal Poverty Level (FPL) may be eligible for free AURYXIA. Additional restrictions apply.

AkebiaCares does not guarantee coverage and/or reimbursement for all patients.

Medicare Part D patients with an annual income of ≤150% of the Federal Poverty Level are eligible for LIS assistance (also called “Extra Help”).

§Copay assistance is not valid for prescriptions reimbursed under Medicare, Medicaid, or similar federal or state programs.

IMPORTANT SAFETY INFORMATION AND INDICATION

CONTRAINDICATION

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

WARNINGS AND PRECAUTIONS

  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

ADVERSE REACTIONS

The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%)

SPECIFIC POPULATIONS

  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

DRUG INTERACTIONS

When clinically significant drug interactions are expected, e.g., Ciprofloxacin or Doxycycline, separate timing of administration.

INDICATION

AURYXIA® (ferric citrate) is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information

REFERENCE

  1. Data on File 31, Akebia Therapeutics, Inc.